AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. COR
  4. [8-K] Cencora, Inc. Reports Material Event

[8-K] Cencora, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Redmile Group, LLC, Jeremy C. Green and RedCo II Master Fund, L.P. have filed Amendment No. 9 to their Schedule 13D on Fate Therapeutics, Inc. (NASDAQ: FATE). The filing, triggered by an event dated 07 July 2025, updates the group鈥檚 ownership disclosure and key blocking provisions.

  • Aggregate beneficial ownership: 17,941,579 common shares (direct and deemed) representing 14.9 % of FATE鈥檚 outstanding common stock (114,633,022 shares as of 6 May 2025).
  • Key holder detail: RedCo II Master Fund holds 13,479,013 shares (11.3 %). All shares are subject to shared voting and dispositive power; no reporting person has sole power.
  • Warrants & preferred stock: 鈥� Pre-Funded Warrants covering 3,691,324 shares (exercise price $0.001) 鈥� Class A Preferred Stock convertible 1-for-5 into up to 810,065 shares (RedCo II) and additional preferred shares across other Redmile funds.
    Both instruments are governed by 14.99 % beneficial-ownership blockers.
  • Change in blocker threshold: On 1 July 2025 Redmile elected to raise the 鈥淢aximum Percentage鈥� under the Warrant Beneficial Ownership Blocker from 9.99 % to 14.99 % (effective 61 days later). This allows the group to exercise additional warrants and approach the new 14.99 % cap without breaching Section 13(d) limits.
  • Funding source: Working capital of various Redmile-managed private investment funds (no external financing disclosed).
  • Historical context: This is the ninth amendment to an initial 13D filed in 2018, reflecting the evolution of Redmile鈥檚 position and security mix (common, warrants, preferred, options, RSUs).

The amendment does not announce new purchases or sales but formalises the larger ownership cap, clarifies the composition of the beneficial stake, and reiterates blocker mechanics designed to limit ownership to 14.99 % of outstanding commons.

Redmile Group, LLC, Jeremy C. Green e RedCo II Master Fund, L.P. hanno presentato la Modifica n. 9 al loro Schedule 13D riguardante Fate Therapeutics, Inc. (NASDAQ: FATE). La comunicazione, scaturita da un evento datato 07 luglio 2025, aggiorna la dichiarazione di propriet脿 del gruppo e le principali clausole di blocco.

  • Propriet脿 complessiva effettiva: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale ordinario di FATE in circolazione (114.633.022 azioni al 6 maggio 2025).
  • Dettaglio dei principali detentori: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri di voto e disposizione condivisi; nessun soggetto ha potere esclusivo.
  • Warrant e azioni privilegiate: 鈥� Warrant prefinanziati per 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1 per 5 fino a un massimo di 810.065 azioni (RedCo II) e ulteriori azioni privilegiate detenute da altri fondi gestiti da Redmile.
    Entrambi gli strumenti sono soggetti a limitazioni di propriet脿 effettiva del 14,99 %.
  • Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha deciso di aumentare la 鈥淧ercentuale Massima鈥� sotto il Blocco di Propriet脿 Beneficiaria dei Warrant dal 9,99 % al 14,99 % (efficace dopo 61 giorni). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
  • Fonte di finanziamento: Capitale operativo di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
  • Contesto storico: Questa 猫 la nona modifica a un 13D iniziale presentato nel 2018, che riflette l鈥檈voluzione della posizione di Redmile e della composizione degli strumenti finanziari (azioni ordinarie, warrant, privilegiate, opzioni, RSU).

La modifica non annuncia nuovi acquisti o vendite, ma formalizza il limite di propriet脿 pi霉 elevato, chiarisce la composizione della partecipazione effettiva e ribadisce i meccanismi di blocco progettati per limitare la propriet脿 al 14,99 % delle azioni ordinarie in circolazione.

Redmile Group, LLC, Jeremy C. Green y RedCo II Master Fund, L.P. han presentado la Enmienda N潞 9 a su Schedule 13D sobre Fate Therapeutics, Inc. (NASDAQ: FATE). La presentaci贸n, originada por un evento fechado el 07 de julio de 2025, actualiza la divulgaci贸n de propiedad del grupo y las principales disposiciones de bloqueo.

  • Propiedad beneficiaria agregada: 17.941.579 acciones comunes (directas y consideradas) que representan el 14,9 % del capital social en circulaci贸n de FATE (114.633.022 acciones al 6 de mayo de 2025).
  • Detalle de los principales titulares: RedCo II Master Fund posee 13.479.013 acciones (11,3 %). Todas las acciones est谩n sujetas a poderes compartidos de voto y disposici贸n; ning煤n informante tiene poder exclusivo.
  • Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3.691.324 acciones (precio de ejercicio $0,001) 鈥� Acciones preferentes Clase A convertibles en una proporci贸n de 1 por 5 hasta un m谩ximo de 810.065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
    Ambos instrumentos est谩n regidos por bloqueos de propiedad beneficiaria del 14,99 %.
  • Cambio en el umbral del bloqueo: El 1 de julio de 2025 Redmile decidi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueo de Propiedad Beneficiaria de Warrants del 9,99 % al 14,99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14,99 % sin infringir los l铆mites de la Secci贸n 13(d).
  • Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privada gestionados por Redmile (no se divulga financiamiento externo).
  • Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n de Redmile y la mezcla de valores (acciones comunes, warrants, preferentes, opciones, RSU).

La enmienda no anuncia nuevas compras o ventas, sino que formaliza el l铆mite mayor de propiedad, aclara la composici贸n de la participaci贸n beneficiaria y reitera los mecanismos de bloqueo dise帽ados para limitar la propiedad al 14,99 % de las acciones comunes en circulaci贸n.

Redmile Group, LLC, Jeremy C. Green 氚� RedCo II Master Fund, L.P.臧� Fate Therapeutics, Inc. (NASDAQ: FATE)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 鞝滌稖鞚� 2025雲� 7鞗� 7鞚�鞐� 氚滌儩頃� 靷贝鞚� 瓿勱赴搿� 攴鸽９鞚� 靻岇湢甓� 瓿店皽 氚� 欤检殧 彀嫧 臁绊暛鞚� 鞐呺嵃鞚错姼頃╇媹雼�.

  • 齑� 鞁れ 靻岇湢甓�: 17,941,579 氤错喌欤�(歆侅爲 氚� 臧勳＜)搿�, 2025雲� 5鞗� 6鞚� 旮办 FATE鞚� 氚滍枆 氤错喌欤� 114,633,022欤� 欷� 14.9 %鞐� 頃措嫻頃╇媹雼�.
  • 欤检殧 氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕鞚� 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅鞚� 鞝侅毄霅橂┌, 雼弲 甓岉暅鞚� 臧�歆� 氤搓碃鞛愲姅 鞐嗢姷雼堧嫟.
  • 鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓 臧�瓴� $0.001鞚� 靹犽偐 鞗岆煱韸� 3,691,324欤� 鈥� RedCo II鞚� 瓴届毎 斓滊寑 810,065欤茧 1雽� 5 鞝勴櫂 臧�電ロ暅 A旮� 鞖办劆欤� 氚� 旮绊儉 Redmile 韼�霌滌潣 於旉皜 鞖办劆欤�.
    霊� 旮堨湹靸來拡 氇憪 14.99% 鞁れ 靻岇湢甓� 彀嫧 攴滌爼鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟.
  • 彀嫧 鞛勱硠臧� 氤�瓴�: 2025雲� 7鞗� 1鞚� Redmile鞚� 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办鞚� 鈥滌禍雽� 牍勳湪鈥濎潉 9.99%鞐愳劀 14.99%搿� 靸來枼 臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�, 鞚措姅 61鞚� 頉� 氚滍毃霅╇媹雼�. 鞚措ゼ 韱淀暣 攴鸽９鞚� 於旉皜 鞗岆煱韸鸽ゼ 頄夓偓頃橁碃 靸堧鞖� 14.99% 頃滊弰鞐� 攴检爲頃� 靾� 鞛堨溂雮�, 13(d) 臁绊暛 頃滊弰毳� 鞙勲皹頃橃 鞎婌姷雼堧嫟.
  • 鞛愱笀 於滌矘: Redmile鞚� 甏�毽晿電� 雼れ枒頃� 靷 韴瀽 韼�霌滌潣 鞖挫爠鞛愲掣(鞕鸽秬 鞛愱笀 臁半嫭鞚� 瓿店皽霅橃 鞎婌潓).
  • 鞐偓鞝� 氚瓣步: 2018雲勳棎 鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳 氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 歆�攵� 氚� 歃濌秾 甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤�頇旊ゼ 氚橃榿頃╇媹雼�.

鞚措矆 靾橃爼鞎堨潃 鞁犼窚 毵れ垬雮� 毵る弰毳� 氚滍憸頃橃 鞎婌溂氅�, 雿� 雴掛潃 靻岇湢 頃滊弰毳� 瓿奠嫕頇旐晿瓿� 鞁れ 歆�攵� 甑劚鞚� 氇呿檿頌� 頃橂┌, 氤挫湢 歆�攵勳潉 14.99%搿� 鞝滍暅頃橁赴 鞙勴暅 彀嫧 氅旍护雼堨鞚� 鞛檿鞚疙暕雼堧嫟.

Redmile Group, LLC, Jeremy C. Green et RedCo II Master Fund, L.P. ont d茅pos茅 l鈥橝mendement n掳 9 脿 leur Schedule 13D concernant Fate Therapeutics, Inc. (NASDAQ : FATE). Le d茅p么t, d茅clench茅 par un 茅v茅nement en date du 7 juillet 2025, met 脿 jour la divulgation de la propri茅t茅 du groupe et les principales dispositions de blocage.

  • Participation b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social en circulation de FATE (114 633 022 actions au 6 mai 2025).
  • D茅tail des principaux d茅tenteurs : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir de vote et de disposition partag茅 ; aucune personne d茅clar茅e ne d茅tient un pouvoir exclusif.
  • Warrants et actions privil茅gi茅es : 鈥� Warrants pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles au ratio de 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) et actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
    Les deux instruments sont soumis 脿 des m茅canismes de blocage limitant la propri茅t茅 b茅n茅ficiaire 脿 14,99 %.
  • Changement du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 pourcentage maximal 禄 sous le bloqueur de propri茅t茅 b茅n茅ficiaire des warrants de 9,99 % 脿 14,99 % (efficace 61 jours plus tard). Cela permet au groupe d鈥檈xercer des warrants suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la section 13(d).
  • Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
  • Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position de Redmile et de la composition des titres (actions ordinaires, warrants, privil茅gi茅es, options, RSU).

L鈥檃mendement n鈥檃nnonce pas de nouveaux achats ou ventes, mais formalise le plafond de propri茅t茅 plus 茅lev茅, clarifie la composition de la participation b茅n茅ficiaire et r茅it猫re les m茅canismes de blocage con莽us pour limiter la propri茅t茅 脿 14,99 % des actions ordinaires en circulation.

Redmile Group, LLC, Jeremy C. Green und RedCo II Master Fund, L.P. haben 脛nderung Nr. 9 zu ihrem Schedule 13D bez眉glich Fate Therapeutics, Inc. (NASDAQ: FATE) eingereicht. Die Einreichung, ausgel枚st durch ein Ereignis vom 7. Juli 2025, aktualisiert die Eigentumsangaben der Gruppe und wichtige Sperrbestimmungen.

  • Gesamtwirtschaftliches Eigentum: 17.941.579 Stammaktien (direkt und als gehalten angesehen), was 14,9 % des ausstehenden Stammaktienkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
  • Details zu Hauptanteilseignern: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen gemeinsamer Stimm- und Verf眉gungsgewalt; keine meldende Person hat Alleinmacht.
  • Warrants & Vorzugsaktien: 鈥� Vorfinanzierte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, die 1:5 in bis zu 810.065 Aktien umwandelbar sind (RedCo II) sowie weitere Vorzugsaktien in anderen Redmile-Fonds.
    Beide Instrumente unterliegen einer 14,99 % wirtschaftlichen Eigentumssperre.
  • 脛nderung der Sperrschwelle: Am 1. Juli 2025 entschied Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant Economic Ownership Blocker von 9,99 % auf 14,99 % zu erh枚hen (wirksam 61 Tage sp盲ter). Dies erlaubt der Gruppe, weitere Warrants auszu眉ben und sich der neuen 14,99 %-Grenze zu n盲hern, ohne die Grenzen von Abschnitt 13(d) zu verletzen.
  • Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
  • Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglichen 13D, das 2018 eingereicht wurde, und spiegelt die Entwicklung von Redmiles Position und Wertpapiermix (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs) wider.

Die 脛nderung k眉ndigt keine neuen K盲ufe oder Verk盲ufe an, sondern formalisert die h枚here Eigentumsobergrenze, kl盲rt die Zusammensetzung des wirtschaftlichen Anteils und bekr盲ftigt die Sperrmechanismen, die darauf ausgelegt sind, den Besitz auf 14,99 % der ausstehenden Stammaktien zu begrenzen.

Positive
  • Redmile鈥檚 stake increases to 14.9 %, indicating sustained confidence from a specialist healthcare investor.
  • Election to raise the beneficial-ownership cap signals intent to maintain or expand exposure, potentially aligning long-term interests with other shareholders.
Negative
  • Potential dilution of up to 4.9 million shares from warrant exercise and preferred conversions once the 14.99 % cap becomes effective.
  • Higher ownership concentration (nearly 15 %) may consolidate voting power and influence, raising governance considerations for minority shareholders.

Insights

TL;DR 鈥� Redmile lifts ownership cap to 14.99 %, reaffirming a large strategic stake without immediate cash impact.

The filing signals continued commitment from a specialist biotech investor. Moving the blocker from 9.99 % to 14.99 % allows Redmile to convert/exercise up to roughly 4.9 million additional shares (options, warrants, preferred) over time. Because the warrants are pre-funded at $0.001, Fate receives negligible incremental cash; the principal impact is potential dilution and voting concentration. No new purchases are disclosed, so near-term float dynamics remain unchanged. Overall, this is structurally important but not fundamentally value-changing in the short term.

TL;DR 鈥� Ownership concentration rises; possible governance influence, but still below 15 % control threshold.

Redmile now controls nearly 15 % of FATE鈥檚 voting power, positioning it as the company鈥檚 leading shareholder. While the firm disclaims control intent, a stake of this size affords meaningful influence over board matters and strategic direction, especially in biotech where floats are limited. The blocker election is a permissible mechanism under SEC rules, but shareholders should watch for future activism or alignment proposals. Because the cap remains below 15 %, poison-pill or change-of-control triggers are unlikely to activate.

Redmile Group, LLC, Jeremy C. Green e RedCo II Master Fund, L.P. hanno presentato la Modifica n. 9 al loro Schedule 13D riguardante Fate Therapeutics, Inc. (NASDAQ: FATE). La comunicazione, scaturita da un evento datato 07 luglio 2025, aggiorna la dichiarazione di propriet脿 del gruppo e le principali clausole di blocco.

  • Propriet脿 complessiva effettiva: 17.941.579 azioni ordinarie (dirette e considerate) che rappresentano il 14,9 % del capitale ordinario di FATE in circolazione (114.633.022 azioni al 6 maggio 2025).
  • Dettaglio dei principali detentori: RedCo II Master Fund detiene 13.479.013 azioni (11,3 %). Tutte le azioni sono soggette a poteri di voto e disposizione condivisi; nessun soggetto ha potere esclusivo.
  • Warrant e azioni privilegiate: 鈥� Warrant prefinanziati per 3.691.324 azioni (prezzo di esercizio $0,001) 鈥� Azioni privilegiate di Classe A convertibili 1 per 5 fino a un massimo di 810.065 azioni (RedCo II) e ulteriori azioni privilegiate detenute da altri fondi gestiti da Redmile.
    Entrambi gli strumenti sono soggetti a limitazioni di propriet脿 effettiva del 14,99 %.
  • Modifica della soglia di blocco: Il 1 luglio 2025 Redmile ha deciso di aumentare la 鈥淧ercentuale Massima鈥� sotto il Blocco di Propriet脿 Beneficiaria dei Warrant dal 9,99 % al 14,99 % (efficace dopo 61 giorni). Ci貌 consente al gruppo di esercitare ulteriori warrant e avvicinarsi al nuovo limite del 14,99 % senza violare i limiti della Sezione 13(d).
  • Fonte di finanziamento: Capitale operativo di vari fondi di investimento privati gestiti da Redmile (nessun finanziamento esterno dichiarato).
  • Contesto storico: Questa 猫 la nona modifica a un 13D iniziale presentato nel 2018, che riflette l鈥檈voluzione della posizione di Redmile e della composizione degli strumenti finanziari (azioni ordinarie, warrant, privilegiate, opzioni, RSU).

La modifica non annuncia nuovi acquisti o vendite, ma formalizza il limite di propriet脿 pi霉 elevato, chiarisce la composizione della partecipazione effettiva e ribadisce i meccanismi di blocco progettati per limitare la propriet脿 al 14,99 % delle azioni ordinarie in circolazione.

Redmile Group, LLC, Jeremy C. Green y RedCo II Master Fund, L.P. han presentado la Enmienda N潞 9 a su Schedule 13D sobre Fate Therapeutics, Inc. (NASDAQ: FATE). La presentaci贸n, originada por un evento fechado el 07 de julio de 2025, actualiza la divulgaci贸n de propiedad del grupo y las principales disposiciones de bloqueo.

  • Propiedad beneficiaria agregada: 17.941.579 acciones comunes (directas y consideradas) que representan el 14,9 % del capital social en circulaci贸n de FATE (114.633.022 acciones al 6 de mayo de 2025).
  • Detalle de los principales titulares: RedCo II Master Fund posee 13.479.013 acciones (11,3 %). Todas las acciones est谩n sujetas a poderes compartidos de voto y disposici贸n; ning煤n informante tiene poder exclusivo.
  • Warrants y acciones preferentes: 鈥� Warrants prefinanciados que cubren 3.691.324 acciones (precio de ejercicio $0,001) 鈥� Acciones preferentes Clase A convertibles en una proporci贸n de 1 por 5 hasta un m谩ximo de 810.065 acciones (RedCo II) y acciones preferentes adicionales en otros fondos de Redmile.
    Ambos instrumentos est谩n regidos por bloqueos de propiedad beneficiaria del 14,99 %.
  • Cambio en el umbral del bloqueo: El 1 de julio de 2025 Redmile decidi贸 aumentar el 鈥淧orcentaje M谩ximo鈥� bajo el Bloqueo de Propiedad Beneficiaria de Warrants del 9,99 % al 14,99 % (efectivo 61 d铆as despu茅s). Esto permite al grupo ejercer warrants adicionales y acercarse al nuevo l铆mite del 14,99 % sin infringir los l铆mites de la Secci贸n 13(d).
  • Fuente de financiamiento: Capital de trabajo de varios fondos de inversi贸n privada gestionados por Redmile (no se divulga financiamiento externo).
  • Contexto hist贸rico: Esta es la novena enmienda a un 13D inicial presentado en 2018, reflejando la evoluci贸n de la posici贸n de Redmile y la mezcla de valores (acciones comunes, warrants, preferentes, opciones, RSU).

La enmienda no anuncia nuevas compras o ventas, sino que formaliza el l铆mite mayor de propiedad, aclara la composici贸n de la participaci贸n beneficiaria y reitera los mecanismos de bloqueo dise帽ados para limitar la propiedad al 14,99 % de las acciones comunes en circulaci贸n.

Redmile Group, LLC, Jeremy C. Green 氚� RedCo II Master Fund, L.P.臧� Fate Therapeutics, Inc. (NASDAQ: FATE)鞐� 雽�頃� Schedule 13D 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 鞝滌稖鞚� 2025雲� 7鞗� 7鞚�鞐� 氚滌儩頃� 靷贝鞚� 瓿勱赴搿� 攴鸽９鞚� 靻岇湢甓� 瓿店皽 氚� 欤检殧 彀嫧 臁绊暛鞚� 鞐呺嵃鞚错姼頃╇媹雼�.

  • 齑� 鞁れ 靻岇湢甓�: 17,941,579 氤错喌欤�(歆侅爲 氚� 臧勳＜)搿�, 2025雲� 5鞗� 6鞚� 旮办 FATE鞚� 氚滍枆 氤错喌欤� 114,633,022欤� 欷� 14.9 %鞐� 頃措嫻頃╇媹雼�.
  • 欤检殧 氤挫湢鞛� 靹鸽秬靷暛: RedCo II Master Fund電� 13,479,013欤�(11.3%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 欤检嫕鞚� 瓿惦彊 韴憸 氚� 觳橂秳 甓岉暅鞚� 鞝侅毄霅橂┌, 雼弲 甓岉暅鞚� 臧�歆� 氤搓碃鞛愲姅 鞐嗢姷雼堧嫟.
  • 鞗岆煱韸� 氚� 鞖办劆欤�: 鈥� 頄夓偓 臧�瓴� $0.001鞚� 靹犽偐 鞗岆煱韸� 3,691,324欤� 鈥� RedCo II鞚� 瓴届毎 斓滊寑 810,065欤茧 1雽� 5 鞝勴櫂 臧�電ロ暅 A旮� 鞖办劆欤� 氚� 旮绊儉 Redmile 韼�霌滌潣 於旉皜 鞖办劆欤�.
    霊� 旮堨湹靸來拡 氇憪 14.99% 鞁れ 靻岇湢甓� 彀嫧 攴滌爼鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟.
  • 彀嫧 鞛勱硠臧� 氤�瓴�: 2025雲� 7鞗� 1鞚� Redmile鞚� 鞗岆煱韸� 鞁れ 靻岇湢甓� 彀嫧旮办鞚� 鈥滌禍雽� 牍勳湪鈥濎潉 9.99%鞐愳劀 14.99%搿� 靸來枼 臁办爼頃橁赴搿� 瓴办爼頄堨溂氅�, 鞚措姅 61鞚� 頉� 氚滍毃霅╇媹雼�. 鞚措ゼ 韱淀暣 攴鸽９鞚� 於旉皜 鞗岆煱韸鸽ゼ 頄夓偓頃橁碃 靸堧鞖� 14.99% 頃滊弰鞐� 攴检爲頃� 靾� 鞛堨溂雮�, 13(d) 臁绊暛 頃滊弰毳� 鞙勲皹頃橃 鞎婌姷雼堧嫟.
  • 鞛愱笀 於滌矘: Redmile鞚� 甏�毽晿電� 雼れ枒頃� 靷 韴瀽 韼�霌滌潣 鞖挫爠鞛愲掣(鞕鸽秬 鞛愱笀 臁半嫭鞚� 瓿店皽霅橃 鞎婌潓).
  • 鞐偓鞝� 氚瓣步: 2018雲勳棎 鞝滌稖霅� 齑堦赴 13D鞚� 鞎勴檳 氩堨Ц 靾橃爼鞎堨溂搿�, Redmile鞚� 歆�攵� 氚� 歃濌秾 甑劚(氤错喌欤�, 鞗岆煱韸�, 鞖办劆欤�, 鞓奠厴, RSU)鞚� 氤�頇旊ゼ 氚橃榿頃╇媹雼�.

鞚措矆 靾橃爼鞎堨潃 鞁犼窚 毵れ垬雮� 毵る弰毳� 氚滍憸頃橃 鞎婌溂氅�, 雿� 雴掛潃 靻岇湢 頃滊弰毳� 瓿奠嫕頇旐晿瓿� 鞁れ 歆�攵� 甑劚鞚� 氇呿檿頌� 頃橂┌, 氤挫湢 歆�攵勳潉 14.99%搿� 鞝滍暅頃橁赴 鞙勴暅 彀嫧 氅旍护雼堨鞚� 鞛檿鞚疙暕雼堧嫟.

Redmile Group, LLC, Jeremy C. Green et RedCo II Master Fund, L.P. ont d茅pos茅 l鈥橝mendement n掳 9 脿 leur Schedule 13D concernant Fate Therapeutics, Inc. (NASDAQ : FATE). Le d茅p么t, d茅clench茅 par un 茅v茅nement en date du 7 juillet 2025, met 脿 jour la divulgation de la propri茅t茅 du groupe et les principales dispositions de blocage.

  • Participation b茅n茅ficiaire agr茅g茅e : 17 941 579 actions ordinaires (directes et r茅put茅es) repr茅sentant 14,9 % du capital social en circulation de FATE (114 633 022 actions au 6 mai 2025).
  • D茅tail des principaux d茅tenteurs : RedCo II Master Fund d茅tient 13 479 013 actions (11,3 %). Toutes les actions sont soumises 脿 un pouvoir de vote et de disposition partag茅 ; aucune personne d茅clar茅e ne d茅tient un pouvoir exclusif.
  • Warrants et actions privil茅gi茅es : 鈥� Warrants pr茅financ茅s couvrant 3 691 324 actions (prix d鈥檈xercice 0,001 $) 鈥� Actions privil茅gi茅es de classe A convertibles au ratio de 1 pour 5 jusqu鈥櫭� 810 065 actions (RedCo II) et actions privil茅gi茅es suppl茅mentaires dans d鈥檃utres fonds Redmile.
    Les deux instruments sont soumis 脿 des m茅canismes de blocage limitant la propri茅t茅 b茅n茅ficiaire 脿 14,99 %.
  • Changement du seuil de blocage : Le 1er juillet 2025, Redmile a choisi d鈥檃ugmenter le 芦 pourcentage maximal 禄 sous le bloqueur de propri茅t茅 b茅n茅ficiaire des warrants de 9,99 % 脿 14,99 % (efficace 61 jours plus tard). Cela permet au groupe d鈥檈xercer des warrants suppl茅mentaires et de s鈥檃pprocher du nouveau plafond de 14,99 % sans enfreindre les limites de la section 13(d).
  • Source de financement : Fonds de roulement de divers fonds d鈥檌nvestissement priv茅s g茅r茅s par Redmile (aucun financement externe d茅clar茅).
  • Contexte historique : Il s鈥檃git du 苍别耻惫颈猫尘别 amendement 脿 un 13D initial d茅pos茅 en 2018, refl茅tant l鈥櫭﹙olution de la position de Redmile et de la composition des titres (actions ordinaires, warrants, privil茅gi茅es, options, RSU).

L鈥檃mendement n鈥檃nnonce pas de nouveaux achats ou ventes, mais formalise le plafond de propri茅t茅 plus 茅lev茅, clarifie la composition de la participation b茅n茅ficiaire et r茅it猫re les m茅canismes de blocage con莽us pour limiter la propri茅t茅 脿 14,99 % des actions ordinaires en circulation.

Redmile Group, LLC, Jeremy C. Green und RedCo II Master Fund, L.P. haben 脛nderung Nr. 9 zu ihrem Schedule 13D bez眉glich Fate Therapeutics, Inc. (NASDAQ: FATE) eingereicht. Die Einreichung, ausgel枚st durch ein Ereignis vom 7. Juli 2025, aktualisiert die Eigentumsangaben der Gruppe und wichtige Sperrbestimmungen.

  • Gesamtwirtschaftliches Eigentum: 17.941.579 Stammaktien (direkt und als gehalten angesehen), was 14,9 % des ausstehenden Stammaktienkapitals von FATE entspricht (114.633.022 Aktien zum 6. Mai 2025).
  • Details zu Hauptanteilseignern: RedCo II Master Fund h盲lt 13.479.013 Aktien (11,3 %). Alle Aktien unterliegen gemeinsamer Stimm- und Verf眉gungsgewalt; keine meldende Person hat Alleinmacht.
  • Warrants & Vorzugsaktien: 鈥� Vorfinanzierte Warrants f眉r 3.691.324 Aktien (Aus眉bungspreis $0,001) 鈥� Klasse A Vorzugsaktien, die 1:5 in bis zu 810.065 Aktien umwandelbar sind (RedCo II) sowie weitere Vorzugsaktien in anderen Redmile-Fonds.
    Beide Instrumente unterliegen einer 14,99 % wirtschaftlichen Eigentumssperre.
  • 脛nderung der Sperrschwelle: Am 1. Juli 2025 entschied Redmile, den 鈥濵aximalprozentsatz鈥� unter dem Warrant Economic Ownership Blocker von 9,99 % auf 14,99 % zu erh枚hen (wirksam 61 Tage sp盲ter). Dies erlaubt der Gruppe, weitere Warrants auszu眉ben und sich der neuen 14,99 %-Grenze zu n盲hern, ohne die Grenzen von Abschnitt 13(d) zu verletzen.
  • Finanzierungsquelle: Betriebskapital verschiedener von Redmile verwalteter privater Investmentfonds (keine externe Finanzierung angegeben).
  • Historischer Kontext: Dies ist die neunte 脛nderung zu einem urspr眉nglichen 13D, das 2018 eingereicht wurde, und spiegelt die Entwicklung von Redmiles Position und Wertpapiermix (Stammaktien, Warrants, Vorzugsaktien, Optionen, RSUs) wider.

Die 脛nderung k眉ndigt keine neuen K盲ufe oder Verk盲ufe an, sondern formalisert die h枚here Eigentumsobergrenze, kl盲rt die Zusammensetzung des wirtschaftlichen Anteils und bekr盲ftigt die Sperrmechanismen, die darauf ausgelegt sind, den Besitz auf 14,99 % der ausstehenden Stammaktien zu begrenzen.

false 0001140859 0001140859 2025-06-30 2025-06-30 0001140859 us-gaap:CommonStockMember 2025-06-30 2025-06-30 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2025-06-30 2025-06-30 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2025-06-30 2025-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 30, 2025

 

Cencora, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   1-16671   23-3079390
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
         

1 West First Avenue
Conshohocken, PA

      

 

19428-1800

(Address of principal executive offices)       (Zip Code)

 

Registrant’s telephone number, including area code:   (610) 727-7000

 

 

Former name or former address, if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of exchange on which
registered
Common stock COR New York Stock Exchange (NYSE)
2.875% Senior Notes 2028 COR New York Stock Exchange (NYSE)
3.625% Senior Notes 2032 COR New York Stock Exchange (NYSE)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 


Amendment of Securitization Facility

 

On June 30, 2025, subsidiaries of Cencora, Inc. (the “Company”) entered into a Twenty-Second Amendment to Amended and Restated Receivables Purchase Agreement (the “Receivables Amendment”), among AmeriSource Receivables Financial Corporation (“ARFC”), as seller, AmerisourceBergen Drug Corporation (“ABDC”), as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd., as administrator.

 

The Receivables Amendment added a new uncommitted purchaser, increased the size of the receivables securitization facility to $1.5 billion from $1.45 billion and amended the Company’s option to increase the commitments of the participating banks, subject to their approval, by an additional $500 million (the “Accordion Feature”), up from $250 million. The Receivables Amendment also made the Accordion Feature available to the Company during any quarter of its fiscal year.

 

The receivables securitization facility is available to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries. Availability under the securitization facility is based on the accounts receivables originated by ABDC and ASD Specialty Healthcare, LLC (“ASD”) from the sale of pharmaceuticals and other related products and services. Pursuant to the receivables securitization facility, ABDC and ASD sell their accounts receivable to ARFC. ARFC may sell interests in the accounts receivables purchased from ABDC and ASD to the various purchaser groups party to the receivables securitization facility, paying program fees on the amount of receivables interests purchased under the facility. The Company serves as the performance guarantor of ASD’s obligations, as originator, and ABDC’s obligations, as originator and servicer, under the receivables securitization facility.

 

The foregoing description of the Receivables Amendment does not purport to be complete and is qualified in its entirety by reference to the Receivables Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 2.03. Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 above is hereby incorporated by reference into this Item 2.03.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)         Exhibits.

 

Exhibit No.

  

Description

10.1   Twenty-Second Amendment to Amended and Restated Receivables Purchase Agreement, dated as of June 30, 2025, among Amerisource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd., as administrator
104   Cover Page Interactive Data File (formatted as inline XBRL)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CENCORA, INC.
     
July 3, 2025 By: /s/ James F. Cleary
  Name: James F. Cleary
  Title: Executive Vice President & Chief Financial Officer

 

 

Source:

FAQ

How many Fate Therapeutics (FATE) shares does Redmile now beneficially own?

The reporting group discloses 17,941,579 shares, or 14.9 % of outstanding common stock.

What change triggered this Schedule 13D/A amendment?

Redmile elected on 1 July 2025 to increase the warrant ownership blocker from 9.99 % to 14.99 %, enabling a larger reportable stake.

Will Fate Therapeutics receive cash from the warrant exercises?

Any remaining Pre-Funded Warrants carry a de-minimis $0.001 exercise price, so cash proceeds will be immaterial.

How much could Redmile鈥檚 position grow post-election?

The group can exercise or convert securities for up to 4.9 million additional shares while staying under the new 14.99 % threshold.

Does the filing suggest imminent share sales by Redmile?

No. The amendment focuses on ownership cap adjustments; it does not indicate sales intentions.

What is the impact on other shareholders?

Dilution risk rises modestly, and governance influence shifts toward a single large holder, but no change-of-control event is triggered.
Stock COR logo
Cencora Inc.

NYSE:COR

COR Rankings

#364 Ranked by Market Cap
#1913 Ranked by Dividends

COR Latest News

Jul 3, 2025
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
May 28, 2025
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
May 7, 2025
Cencora Reports Fiscal 2025 Second Quarter Results
Mar 28, 2025
Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release
Feb 6, 2025
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

COR Latest SEC Filings

Jul 2, 2025
[Form 4] Cencora, Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] Cencora, Inc. Insider Trading Activity
Jun 24, 2025
[144] Cencora, Inc. SEC Filing
Jun 20, 2025
[Form 4] Cencora, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Cencora, Inc. Insider Trading Activity

COR Stock Data

57.48B
183.55M
6.85%
92.69%
3.58%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
United States
CONSHOHOCKEN